Media headlines about SCYNEXIS (NASDAQ:SCYX) have been trending somewhat positive recently, according to Accern. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. SCYNEXIS earned a coverage optimism score of 0.12 on Accern’s scale. Accern also gave news headlines about the company an impact score of 45.7469468521266 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:
- Scynexis Inc (SCYX) CEO Marco Taglietti Bought $169000 of Shares – GuruFocus.com (gurufocus.com)
- SCYNEXIS Reports Full Year 2017 Financial Results and Provides Company Update (finance.yahoo.com)
- Technical Fundamentals and Valuation: Scynexis Inc Cmn (SCYX) and Oncomed Pharma (OMED) – Post Registrar (postregistrar.com)
- SCYNEXIS, Inc. (NASDAQ:SCYX) – Active Mover – Nasdaq Journal (nasdaqjournal.com)
- Gonzalez David Angulo Buys 14,790 Shares of SCYNEXIS Inc (SCYX) Stock (americanbankingnews.com)
SCYX has been the subject of a number of research reports. ValuEngine raised SCYNEXIS from a “strong sell” rating to a “sell” rating in a research note on Saturday, December 9th. Zacks Investment Research cut SCYNEXIS from a “buy” rating to a “hold” rating in a research note on Saturday, December 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the stock. SCYNEXIS currently has an average rating of “Hold” and an average target price of $7.75.
In related news, CEO Marco Taglietti bought 100,000 shares of the company’s stock in a transaction dated Thursday, March 8th. The shares were bought at an average price of $1.69 per share, for a total transaction of $169,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 404,000 shares of the company’s stock, valued at $682,760. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders bought 135,500 shares of company stock worth $228,995 in the last 90 days. Corporate insiders own 4.00% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “SCYNEXIS (SCYX) Receives Coverage Optimism Score of 0.12” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3264451/scynexis-scyx-receives-coverage-optimism-score-of-0-12.html.
SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.